ProCE Banner Activity

BTK Inhibitors for Managing Patients with B-Cell Malignancies: Safety and Optimal Use

Slideset Download
Download these slides from our ASH 2019 live satellite symposium on safety and optimal use of BTK inhibitors to review the most current clinical data on treating patients with hematologic malignancies.

Released: December 06, 2019

Expiration: December 04, 2020

No longer available for credit.

Share

Faculty

Alexey Danilov

Alexey Danilov, MD

Associate Professor of Medicine
Department of Hematology/Oncology
Knight Cancer Institute
Oregon Health and Science University
Portland, Oregon

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

BeiGene, Ltd.

Loxo Oncology subsidiary of Eli Lilly

Faculty Disclosure

Primary Author

Alexey Danilov, MD

Associate Professor of Medicine
Department of Hematology/Oncology
Knight Cancer Institute
Oregon Health and Science University
Portland, Oregon

Alexey Danilov, MD, has disclosed that he has received funds for research support from Aptose Bio, AstraZeneca, Bayer Oncology, Bristol-Meyers-Squibb, Genentech, Gilead Sciences, MEI Pharma, Takeda Oncology, and Verastem Oncology, as well as consulting fees from AstraZeneca, BeiGene, Celgene, Curis, Genentech, Gilead Sciences, Janssen, Juno, Pharmacyclics, Teva Oncology, TG Therapeutics, and Verastem Oncology.